◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › RLMD

Relmada Therapeutics, Inc. (RLMD) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-13

Relmada Therapeutics, Inc. (RLMD) operates in the Biotechnology industry and is headquartered in Coral Gables, United States with about 17 employees. Its market capitalization is roughly $677 million. In the fiscal year ended 2025-12-31, RLMD reported $0M in revenue and ($57M) in net income.

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Interactive charts & full statements →

RLMD Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($59M)($84M)($104M)($161M)
Net Income($57M)($80M)($99M)($157M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($20M)($20M)($10M)($10M)($18M)
Net Income($19M)($20M)($10M)($10M)($18M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RLMD Free Cash Flow History

RLMD Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$94M$46M$98M$153M
Total Liabilities$8M$10M$12M$12M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RLMD viewer.

Other Companies in Biotechnology

← RLIAll stocksRLYB →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.